Trevi Therapeutics (TRVI) Change in Account Payables (2018 - 2026)
Trevi Therapeutics' (TRVI) quarterly Change in Account Payables came in at -$1.5 million in Q1 2026, up 25.59% year-on-year from -$1.2 million in Q1 2025, and down 1305.69% quarter-over-quarter from $123000.0 in Q4 2025.
Trevi Therapeutics (TRVI) Change in Account Payables (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Change in Account Payables history runs 9 years deep, the most recent figure standing at -$1.5 million for Q1 2026.
- On a quarterly basis, Change in Account Payables rose 25.59% year-over-year to -$1.5 million in Q1 2026; TTM through Mar 2026 was -$88000.0, a 87.1% increase from a year earlier, with the FY2025 full-year figure at -$598000.0, down 137.26% from the prior year.
- Change in Account Payables fell to -$1.5 million in Q1 2026 per TRVI's latest filing, from $123000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $2.1 million in Q2 2022 and bottomed at -$2.0 million in Q1 2025.
- The 5-year median for Change in Account Payables is -$170000.0 (2023), against an average of -$89176.5.
- Biggest YoY gain for Change in Account Payables was 351.46% in 2025; the steepest drop was 777.89% in 2025.
- Year by year, Change in Account Payables stood at $536000.0 in 2022, then rose by 16.98% to $627000.0 in 2023, then soared by 186.92% to $1.8 million in 2024, then sank by 93.16% to $123000.0 in 2025, then tumbled by 1305.69% to -$1.5 million in 2026.
- Per Business Quant, the three latest TRVI Change in Account Payables figures stand at -$1.5 million (Q1 2026), $123000.0 (Q4 2025), and -$282000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Trevi Therapeutics | 2.50 Bn | 2.50 Bn | - | -1.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.48 Mn |
| Mar 31, 2026 | -1.48 Mn |
| Dec 31, 2025 | 123,000.00 |
| Dec 31, 2025 | 123,000.00 |
| Sep 30, 2025 | -282,000.00 |
| Sep 30, 2025 | -282,000.00 |
| Jun 30, 2025 | 1.55 Mn |
| Jun 30, 2025 | 1.55 Mn |
| Mar 31, 2025 | -1.99 Mn |
| Mar 31, 2025 | -1.99 Mn |
| Dec 31, 2024 | 1.80 Mn |
| Dec 31, 2024 | 1.80 Mn |
| Sep 30, 2024 | 130,000.00 |
| Sep 30, 2024 | 130,000.00 |
| Jun 30, 2024 | -618,000.00 |
| Jun 30, 2024 | -618,000.00 |
| Mar 31, 2024 | 294,000.00 |
| Mar 31, 2024 | 294,000.00 |
| Dec 31, 2023 | 627,000.00 |
| Dec 31, 2023 | 627,000.00 |